C56 Malignant neoplasm of ovary

Name of the Condition

• Malignant neoplasm of ovary
• Ovarian cancer

Summary

Malignant neoplasm of the ovary, commonly referred to as ovarian cancer, is a cancerous growth that originates in the ovarian tissue. It involves the abnormal proliferation of cells that can invade nearby structures or spread to distant parts of the body if not addressed. Ovarian cancer is often diagnosed at an advanced stage due to subtle early symptoms.

Causes

The exact cause of ovarian cancer is not fully understood, but it is associated with genetic mutations, such as BRCA1 and BRCA2, and alterations in cell growth regulation. Other contributing factors may include hormonal imbalances and environmental influences, though specific triggers remain under investigation.

Risk Factors

• Age: Most common in women over 50
• Family history: Having close relatives with ovarian, breast, or colorectal cancer
• Genetic mutations: BRCA1, BRCA2, or Lynch syndrome
• Reproductive history: Nulliparity or late first pregnancy
• Hormonal factors: Long-term estrogen exposure without progesterone
• Obesity: Higher body mass index (BMI)
• Endometriosis: Chronic uterine lining tissue outside the uterus

Symptoms

• Abdominal or pelvic pain, bloating, or pressure
• Persistent changes in bowel or bladder habits
• Unexplained weight loss or loss of appetite
• Fatigue or feeling full quickly
• Abnormal vaginal bleeding or discharge

Diagnosis

Diagnosis typically begins with a pelvic examination and imaging studies, such as transvaginal ultrasound or CT scans, to assess ovarian structure. Blood tests, including CA-125 or other tumor markers, may support suspicion. A definitive diagnosis requires a biopsy, often obtained during surgery, to confirm malignant cell presence and grade.

Treatment Options

• Surgery: Removal of the tumor, ovary, fallopian tube, or uterus (hysterectomy) depending on extent
• Chemotherapy: Systemic or intraperitoneal drug therapy to target remaining cells
• Targeted therapy: Drugs targeting specific genetic mutations (e.g., PARP inhibitors)
• Radiation therapy: Less common, used for localized or palliative care

Prognosis and Follow-Up

Prognosis depends on the cancer stage, grade, and response to treatment. Early-stage disease has a better outlook, while advanced cases may have a poorer prognosis. Follow-up includes regular imaging, CA-125 monitoring, and physical exams to detect recurrence. Long-term surveillance is standard.

Complications

• Metastasis: Spread to peritoneum, lymph nodes, liver, or lungs
• Bowel obstruction: From tumor growth or treatment effects
• Ascites: Fluid buildup in the abdomen
• Thromboembolism: Increased risk of blood clots
• Infertility: From surgical or chemotherapeutic interventions

Lifestyle & Prevention

• Genetic counseling: For those with family history or known mutations
• Oral contraceptives: May reduce risk with long-term use
• Healthy weight maintenance: Lower BMI associated with reduced risk
• Breastfeeding: Linked to decreased ovarian cancer risk
• Avoiding unnecessary hormone therapy: Discuss risks with a provider

When to Seek Professional Help

Seek care if experiencing persistent abdominal pain, bloating, or unexplained weight loss lasting more than two weeks. Early evaluation is critical for timely diagnosis and treatment. Prompt attention to changes in bowel or bladder habits is also advised.

Tips for Medical Coders

Use C56 for malignant neoplasm of the ovary when the site is unspecified or bilateral. Document laterality (e.g., right/left) or specific ovary involvement if known, as this may require additional codes. Ensure documentation supports the diagnosis, including histopathology or imaging findings, to validate code assignment.